1-methyl-1H-indole-4-sulfonyl chloride → 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-{1-[(1-methyl-1H-indol-4-yl)sulfonyl]piperidin-4-yl}-2,4-dihydro-3H-pyrazol-3-one

HRID 1914164

反応式

HRID 1914164 の反応式
Cl.[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][NH:20][CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11].[CH3:26][N:27]1[C:35]2[CH:34]=[CH:33][CH:32]=[C:31]([S:36](Cl)(=[O:38])=[O:37])[C:30]=2[CH:29]=[CH:28]1>>[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][N:20]([S:36]([C:31]4[CH:32]=[CH:33][CH:34]=[C:35]5[C:30]=4[CH:29]=[CH:28][N:27]5[CH3:26])(=[O:37])=[O:38])[CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11]

参加物

3

反応物 2

HCID 185257821-methyl-1H-indole-4-sulfonyl chlorideHCID 666164065-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-piperidin-4-yl-2,4-dihydro-3H-pyrazol-3-one hydrochloride2 回

生成物 1

HCID 673643805-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-{1-[(1-methyl-1H-indol-4-yl)sulfonyl]piperidin-4-yl}-2,4-dihydro-3H-pyrazol-3-one

実験手順

The title compound is prepared analogously as described for GP1 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-(piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one (compound B1) and 1-methyl-1H-indole-4-sulfonyl chloride as starting compounds. The crude product is purified by crystallization from EA and diethyl ether to yield the title compound.

後処理

  1. customThe title compound is prepared analogously
  2. customThe crude product is purified by crystallization from EA and diethyl ether

出典と根拠

ORDレコード
ord-e8e3db4b558d4e2fbb3af7b190932a27
出典データセット
uspto-grants-2013_12
特許番号
US08609848B2

関連ノート

読み込み中…